Albany Molecular says Bristol-Myers stops development of depression drug
Aug 12 (Reuters) - Albany Molecular Research Inc said partner Bristol-Myers Squibb Co would stop developing their experimental depression therapy.
Albany's shares tumbled 19 percent to $10.24 in afternoon trading.
Albany said Bristol-Myers stopped two mid-stage studies of the drug after it failed to show superiority over two other antidepressants. (link.reuters.com/fax32v)
Albany said the decision would not have an impact on its forecasts for the third quarter and 2013. (Reporting by Pallavi Ail in Bangalore; Editing by Saumyadeb Chakrabarty)
- Washington wins diplomatic support for campaign in Iraq; Syria trickier |
- Apple iPhone 6 pre-orders hit record 4 million on first day |
- Western sanctions are testing Russia's strength: Medvedev |
- Alibaba worried about Facebook IPO as considered Nasdaq versus NYSE |
- Exclusive: Two Apple medical trials shed light on how HealthKit will work